Company
Eli Lilly
- Episodes
- 4
- Share
- 0.4%
- Shows
- 4
- Net sentiment
- +1.00
Down from 0.8% of episodes in the weeks before; net sentiment was +0.69.
Bullish 4Mixed 0Neutral 0Bearish 0
3 weeks
Share of each week's episodes naming it, and net sentiment.
0%2%4%
Sep 21Sep 28Oct 5
Net sentiment
−10+1
Sep 21Sep 28Oct 5
The episodes that named it
Why each one was bullish, bearish or in between on Eli Lilly. Longest episodes first.
Bullish 4
- Analysts see Lilly's pipeline and new cancer drug label reinforcing its obesity market leadership.Closing Bell 10/7/26 · Closing Bell · Oct 7
- Reportedly acquired a psychedelics company for about $2.8 billion, signaling mainstream acceptance.3 businesses we think are about to blow up · My First Million · Oct 5
- Shares rose on early data suggesting GLP-1 drugs may slow biological aging.Rates Back On The Rise… And Used Car Market Shifting Into Reverse 10/7/26 · CNBC's "Fast Money" · Oct 7
- Eisman believes Lilly has won the diet drug market with no sign of change soon.“Big Short” Investor Steve Eisman Isn’t Calling a Crash—But He Sees One Big Risk · In the Money with Amber Kanwar · Oct 8
Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.
Briefs like this, for everything you follow.
Ethmos puts research agents on your coverage universe — every debate that touches your names, every executive appearance you'd have missed — and files briefs every morning.
Start free14-day free trial